Acute Migraine Drugs Sales

Acute Migraine Drugs Sales Market Outlook

The global acute migraine drugs market is expected to reach approximately USD 5.3 billion by 2035, growing at a compound annual growth rate (CAGR) of 5.5% from 2025 to 2035. The increasing prevalence of migraines and the growing awareness regarding effective treatment options are significant factors contributing to this market growth. Additionally, the ongoing development of innovative drug formulations and the expansion of healthcare infrastructure in emerging economies are expected to further enhance market dynamics. Moreover, the rising number of patients seeking immediate relief from migraine attacks is pushing pharmaceutical companies to invest in research and development to provide more effective solutions. Thus, all these factors collectively contribute to the robust growth anticipated in this sector.

Growth Factor of the Market

The acute migraine drugs market is witnessing substantial growth due to several key factors. Firstly, the increasing incidence of migraines across various demographics, particularly among working adults, has created a heightened demand for effective treatment options. Furthermore, improved diagnostic methods and increased awareness regarding migraine triggers are encouraging more individuals to seek medical assistance, resulting in a surge in drug prescriptions. Additionally, the introduction of novel drug delivery systems, such as nasal sprays and oral dissolvable tablets, is appealing to patients who prefer more convenient treatment methods. Moreover, the expansion of telemedicine has made it easier for patients to consult healthcare professionals and gain access to migraine relief medications, thereby driving market growth. Lastly, the focus of pharmaceutical companies on continuous product innovation and the introduction of combination therapies are expected to further contribute to the market's expansion.

Key Highlights of the Market

• The market is projected to witness significant growth due to the rising prevalence of migraines globally.
• Innovations in drug formulations and delivery systems are enhancing treatment options for patients.
• Increased healthcare spending and improved access to medical facilities are facilitating market growth.
• The rise of telemedicine is broadening patient access to migraine treatments.
• Pharmaceutical companies are focusing on R&D to develop more effective and targeted migraine therapies.

By Product Type

Triptans:

Triptans are among the most commonly prescribed medications for acute migraine treatment, recognized for their efficacy in alleviating migraine symptoms. These drugs work by stimulating serotonin receptors in the brain, which helps to constrict dilated blood vessels and reduce inflammation. The triptan segment is expected to dominate the market due to their established effectiveness and the wide variety of formulations available, including oral, subcutaneous, and nasal spray options. Their rapid onset of action makes them a preferred choice among healthcare providers, further contributing to their market share. Additionally, increasing FDA approvals for new triptan formulations are likely to bolster this segment’s growth, catering to the evolving needs of patients who require swift relief from migraine attacks.

NSAIDs:

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) represent another significant product type in the acute migraine drugs market. Medications like ibuprofen and naproxen are often utilized for migraine relief due to their anti-inflammatory and analgesic properties. The NSAID segment is driven by their over-the-counter availability, making them easily accessible to consumers. Furthermore, as patients increasingly seek cost-effective treatment options, NSAIDs are gaining traction in both clinical settings and retail pharmacies. The versatility of NSAIDs also allows them to be used in combination with other medications, enhancing their effectiveness for migraine sufferers. Their established safety profiles and long history of use contribute to patient trust and preference, solidifying their role in the market.

Ergot Alkaloids:

Ergot alkaloids, which include medications such as dihydroergotamine, have been used for decades as acute treatments for migraines. These drugs act as vasoconstrictors, targeting the blood vessels in the brain to alleviate migraine symptoms. While the ergot alkaloids segment is smaller compared to triptans and NSAIDs, it still plays a crucial role in treatment, particularly for patients who do not respond well to other medications. The continued development of ergot derivatives and novel formulations is expected to revitalize this segment, enhancing patient compliance and expanding its market reach. Moreover, healthcare providers are often inclined to prescribe ergot alkaloids for patients experiencing frequent attacks, thus sustaining their relevance in acute migraine management.

Acetaminophen:

Acetaminophen is a widely recognized analgesic that can effectively relieve mild to moderate migraine pain. It is often recommended as a first-line treatment for patients who may be contraindicated for stronger medications. The acetaminophen segment benefits from its over-the-counter status, enabling easy access for patients suffering from migraines. Moreover, the low side-effect profile of acetaminophen makes it an appealing option for patients, especially those who may experience adverse reactions to NSAIDs or triptans. The affordability and widespread availability of acetaminophen further contribute to its sustained presence in the market, particularly for individuals seeking quick relief without the need for a prescription.

Others:

The "Others" category encompasses a variety of emerging and alternative treatment options for acute migraines, including herbal supplements, anti-nausea medications, and adjunct therapies. This segment is gradually gaining traction as patients explore holistic and integrative approaches to migraine management. The increasing interest in natural remedies and non-pharmacological treatments is driving the growth of this segment, as patients seek additional ways to complement traditional medications. As research continues to validate the effectiveness of certain alternative treatments, the "Others" segment may see a notable expansion, attracting patients who are looking for personalized and diverse approaches to managing their migraines.

By Application

Hospitals:

Hospitals play a significant role in the administration of acute migraine medications, particularly for severe cases requiring immediate medical attention. Emergency departments often treat patients with debilitating migraines, using a combination of medications to provide rapid relief. The hospital segment is projected to witness growth as the number of patients seeking care for acute migraine attacks increases. Additionally, advancements in hospital infrastructure and the availability of specialized headache clinics enhance the capacity to manage migraine sufferers effectively. Enhanced collaboration between neurologists and emergency department staff ensures a comprehensive approach to treating migraines, thereby fostering a supportive environment for patients requiring acute care.

Clinics:

Clinics represent an essential avenue for acute migraine treatment, often providing a more personalized approach to patient care compared to hospital settings. Neurology and headache clinics specialize in diagnosing and managing migraines, enabling healthcare providers to tailor treatment plans based on individual patient needs. This segment is experiencing growth due to the increasing recognition of migraines as a chronic condition requiring ongoing management. As patients seek more specialized care, clinics are becoming pivotal in offering education, preventive strategies, and acute treatment options. Enhanced patient engagement and follow-up care further solidify the clinic segment's significance in the acute migraine drugs market.

Retail Pharmacies:

Retail pharmacies serve as a primary access point for patients seeking over-the-counter migraine relief medications, such as NSAIDs and acetaminophen. The convenience and accessibility of retail pharmacies make them a popular choice for individuals experiencing mild to moderate migraine pain. The retail pharmacy segment is expected to grow as consumers increasingly prefer self-management solutions for their health concerns. Furthermore, marketing campaigns and pharmacist consultations are raising awareness about available treatment options, prompting more patients to seek relief from migraines. The growing trend towards preventive care and health education within retail pharmacies is also contributing to the segment's expansion, as pharmacists play an active role in guiding patients toward appropriate therapies.

e-Commerce:

The rise of e-commerce in the pharmaceutical sector has transformed how patients access acute migraine medications. Online platforms provide convenience and discretion, allowing individuals to purchase medications from the comfort of their homes. The e-commerce segment is witnessing substantial growth, particularly among younger demographics who prefer digital shopping experiences. Additionally, the COVID-19 pandemic accelerated the adoption of telehealth services and online pharmacies, enabling patients to consult healthcare providers and order medications online seamlessly. This segment is expected to continue expanding, driven by the increasing reliance on digital platforms for healthcare solutions and the growing trend of home delivery services for medications.

By Distribution Channel

Prescription-based:

The prescription-based distribution channel remains a crucial avenue for dispensing acute migraine medications, particularly for stronger drugs like triptans and ergot alkaloids. This segment is characterized by the necessity for patients to consult healthcare professionals before receiving medication, ensuring that appropriate treatments are provided based on individual patient profiles. The prescription-based segment benefits from ongoing advancements in telemedicine, which facilitates easier access to healthcare professionals, especially for those who may experience barriers to in-person consultations. Furthermore, the increasing prevalence of chronic migraine conditions is expected to drive demand for prescribed treatments, as healthcare providers aim to offer personalized care and effective migraine management strategies.

Over-the-Counter:

The over-the-counter (OTC) distribution channel is pivotal for delivering acute migraine relief to consumers who prefer to manage their symptoms independently. This segment includes widely accessible medications such as acetaminophen, NSAIDs, and certain combination therapies. The OTC market is thriving due to rising consumer awareness regarding self-care and the convenience of obtaining medications without prescriptions. Additionally, recent trends indicate that patients are more inclined to seek OTC options as an initial treatment approach for mild migraines, contributing to the growth of this segment. The marketing efforts by pharmaceutical companies to promote the efficacy of OTC products are further enhancing consumer confidence and driving sales in this channel.

By Ingredient Type

Sumatriptan:

Sumatriptan is one of the most widely prescribed medications for the acute treatment of migraines, playing a key role in the triptan category. As an effective vasoconstrictor, sumatriptan targets serotonin receptors to alleviate migraine symptoms swiftly. Its availability in various formulations, including injectables, nasal sprays, and oral tablets, makes it a versatile option for patients. The growing preference for rapid-acting medications is expected to contribute to the continued demand for sumatriptan. Furthermore, ongoing studies into its long-term safety and efficacy will likely bolster its use as a first-line treatment for many patients experiencing frequent migraine attacks.

Ibuprofen:

Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) that is commonly used for managing mild to moderate migraine pain. Its affordability and over-the-counter availability make it a popular choice among consumers seeking quick relief. As a well-established medication, ibuprofen is known for its effective analgesic and anti-inflammatory properties, which help in alleviating headache symptoms. The widespread acceptance of ibuprofen as a first-line treatment for migraines ensures its continued relevance in the market. Furthermore, the trend toward self-medication and the increasing focus on preventive strategies among patients are expected to sustain the growth of ibuprofen in the acute migraine drugs segment.

Diclofenac:

Diclofenac is another NSAID that is often utilized for acute migraine management, recognized for its anti-inflammatory and analgesic properties. It is commonly prescribed for patients who may experience insufficient relief from first-line treatments. The diclofenac segment is experiencing growth due to its effectiveness in reducing migraine symptoms and the increasing availability of various formulations, including oral and topical applications. As healthcare providers continue to explore alternative treatment options for patients with acute migraines, diclofenac is becoming a viable choice, particularly for those seeking fast and effective pain relief. The continued research into its long-term benefits and potential combination therapies will likely enhance its role in the acute migraine drugs market.

Rizatriptan:

Rizatriptan is a selective serotonin receptor agonist that is effective in treating acute migraine attacks. It is known for its rapid onset of action and is available in both oral and orally disintegrating tablet forms, making it a convenient option for patients. The growing acceptance of rizatriptan among healthcare providers has led to an increase in prescriptions, particularly among patients who seek immediate relief from migraine pain. The continuous innovation surrounding rizatriptan formulations is expected to attract more patients, thereby expanding its market presence. Additionally, ongoing clinical trials exploring its efficacy in combination with other migraine therapies will contribute to its future growth potential in the acute migraine drugs market.

Others:

The "Others" category comprises various emerging ingredients and alternative therapies aimed at treating acute migraines. This segment includes herbal supplements, non-pharmacological approaches, and adjunct therapies that are gaining popularity among patients seeking holistic treatment options. The increasing awareness of natural remedies and their benefits in managing migraine symptoms is driving growth in this segment. As research continues to validate the effectiveness of these alternative treatments, patients are likely to explore diverse avenues for migraine relief, making this category an essential part of the overall acute migraine drugs market. Moreover, the ongoing exploration of synergistic therapies that combine traditional and alternative options will further enhance the relevance of this segment.

By Region

The North American region is anticipated to lead the acute migraine drugs market, accounting for a significant share driven by the high prevalence of migraine disorders and the robust healthcare infrastructure. The United States, in particular, dominates the market due to the widespread availability of acute migraine medications and increasing healthcare expenditures. The region is projected to grow at a CAGR of 6.2% during the forecast period, reflecting the ongoing advancements in migraine treatments and the rising trend for self-medication options. Additionally, the growing emphasis on patient education and awareness programs within the region is likely to encourage more individuals to seek appropriate treatment for their migraine symptoms.

In Europe, the acute migraine drugs market is also experiencing considerable growth, with countries like Germany, France, and the United Kingdom leading the way. The European market benefits from a well-established healthcare system and a rising prevalence of migraine disorders. Increased investments in research and development by pharmaceutical companies and the growing focus on innovative drug formulations are driving growth in this region. Furthermore, the increasing popularity of telehealth services in Europe is enhancing patient access to migraine treatments and consultations, thereby contributing to the overall market expansion. The European acute migraine drugs market is projected to grow steadily, supported by a favorable regulatory environment and healthcare policies aimed at improving patient outcomes.

Opportunities

The acute migraine drugs market presents numerous opportunities for growth and innovation, particularly as the demand for effective treatment options continues to rise. One of the significant opportunities lies in the development of novel drug formulations that incorporate advanced delivery systems, such as transdermal patches and inhalable medications. These innovative approaches could provide quick relief while minimizing side effects, attracting both healthcare providers and patients. Additionally, the integration of digital health solutions, including mobile applications for tracking migraine triggers and medication adherence, can enhance patient engagement and treatment outcomes. As patients increasingly seek personalized healthcare solutions, there is potential for pharmaceutical companies to develop tailored treatments that cater to specific patient demographics or preferences.

Moreover, expanding market presence in emerging economies represents a substantial opportunity for growth in the acute migraine drugs market. As healthcare systems in regions such as Asia Pacific and Latin America continue to develop, the increasing accessibility of medications and healthcare services will drive demand for effective migraine treatments. Pharmaceutical companies can leverage partnerships with local distributors and healthcare providers to improve product availability and raise awareness about migraine management. Furthermore, the growing emphasis on preventive care and education in these markets can create additional opportunities for companies to introduce preventive migraine therapies, ultimately contributing to a greater understanding of migraine conditions and their treatments.

Threats

Despite the promising growth outlook for the acute migraine drugs market, several threats could hinder its progress. One major threat comes from the emergence of generic drugs and biosimilars, which pose competition to established branded medications. As patents for various acute migraine treatments expire, generic alternatives may flood the market, potentially leading to price erosion and reduced revenues for pharmaceutical companies. This trend could result in increased pressure to innovate and differentiate products to maintain market share. Additionally, the growing trend of self-medication could lead to patients opting for OTC solutions rather than seeking professional medical advice, which may hinder effective management of migraine conditions and reduce the reliance on prescription medications.

Another critical challenge facing the market is the potential for regulatory changes that could impact the approval and marketing of acute migraine drugs. Stringent regulations regarding drug efficacy and safety could result in delays in bringing new products to market, thereby affecting the competitive landscape. Moreover, the increasing scrutiny on pharmaceutical pricing practices may lead to heightened public demand for affordable treatment options, driving companies to reassess pricing strategies and potentially impacting profit margins. The ongoing challenges posed by counterfeit drugs and illicit online sales further underscore the need for robust regulatory frameworks and patient education initiatives to protect consumer safety and ensure effective migraine management.

Competitor Outlook

• AbbVie Inc.
• Pfizer Inc.
• GlaxoSmithKline plc
• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.
• Eli Lilly and Company
• Merck & Co., Inc.
• Horizon Therapeutics plc
• Novartis AG
• Zydus Cadila
• Dr. Reddy's Laboratories
• Sanofi S.A.
• Sumitomo Dainippon Pharma Co., Ltd.
• Alnylam Pharmaceuticals, Inc.
• Impax Laboratories LLC

The competitive landscape of the acute migraine drugs market is characterized by a mix of established pharmaceutical companies and emerging players vying for market share. Major companies like AbbVie, Pfizer, and GlaxoSmithKline have maintained a strong presence in the market with their well-known migraine treatments, including triptans and NSAIDs. These companies are heavily invested in research and development to innovate and diversify their product portfolios, which enhances their competitive advantage. Additionally, collaborations and partnerships between pharmaceutical companies and research institutions are becoming increasingly common, facilitating the development of novel migraine treatments and expanding market access.

Furthermore, the shift toward personalized medicine is reshaping the competitive landscape, as companies strive to create targeted therapies based on genetic profiles and patient characteristics. This trend presents opportunities for smaller biotechnology firms to innovate and introduce unique solutions that cater to niche markets within the migraine treatment sector. Additionally, companies that leverage digital health technologies, such as telehealth applications and online patient support platforms, are well-positioned to capture the attention of tech-savvy consumers seeking convenient and effective healthcare solutions.

Key players in the acute migraine drugs market are not only focusing on product innovation but are also addressing pricing pressures and regulatory compliance. For instance, companies like Amgen and Eli Lilly have made substantial investments in value-based pricing models, aiming to demonstrate the efficacy and cost-effectiveness of their migraine treatments. The competitive dynamics are further enhanced by increasing patient advocacy and awareness campaigns that empower individuals to seek effective treatment options. As the market continues to evolve, companies will need to adapt their strategies to remain competitive and address the ever-changing landscape of migraine management.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Amgen Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 AbbVie Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Novartis AG
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Pfizer Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Sanofi S.A.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Zydus Cadila
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Merck & Co., Inc.
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 GlaxoSmithKline plc
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Eli Lilly and Company
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Impax Laboratories LLC
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Dr. Reddy's Laboratories
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Horizon Therapeutics plc
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Alnylam Pharmaceuticals, Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Sumitomo Dainippon Pharma Co., Ltd.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Teva Pharmaceutical Industries Ltd.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Acute Migraine Drugs Sales Market, By Application
    • 6.1.1 Hospitals
    • 6.1.2 Clinics
    • 6.1.3 Retail Pharmacies
    • 6.1.4 e-Commerce
  • 6.2 Acute Migraine Drugs Sales Market, By Product Type
    • 6.2.1 Triptans
    • 6.2.2 NSAIDs
    • 6.2.3 Ergot Alkaloids
    • 6.2.4 Acetaminophen
    • 6.2.5 Others
  • 6.3 Acute Migraine Drugs Sales Market, By Ingredient Type
    • 6.3.1 Sumatriptan
    • 6.3.2 Ibuprofen
    • 6.3.3 Diclofenac
    • 6.3.4 Rizatriptan
    • 6.3.5 Others
  • 6.4 Acute Migraine Drugs Sales Market, By Distribution Channel
    • 6.4.1 Prescription-based
    • 6.4.2 Over-the-Counter

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Acute Migraine Drugs Sales Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Acute Migraine Drugs Sales market is categorized based on

By Product Type

• Triptans
• NSAIDs
• Ergot Alkaloids
• Acetaminophen
• Others

By Application

• Hospitals
• Clinics
• Retail Pharmacies
• e-Commerce

By Distribution Channel

• Prescription-based
• Over-the-Counter

By Ingredient Type

• Sumatriptan
• Ibuprofen
• Diclofenac
• Rizatriptan
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• AbbVie Inc.
• Pfizer Inc.
• GlaxoSmithKline plc
• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.
• Eli Lilly and Company
• Merck & Co., Inc.
• Horizon Therapeutics plc
• Novartis AG
• Zydus Cadila
• Dr. Reddy's Laboratories
• Sanofi S.A.
• Sumitomo Dainippon Pharma Co., Ltd.
• Alnylam Pharmaceuticals, Inc.
• Impax Laboratories LLC